MKMiia Kovalainen

Miia Kovalainen

*This is an algorithmically generated author record based on publicly available information.

Miia Kovalainen has a total of 100 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Supersaturated Silica-Lipid Hybrid Oral Drug Delivery Systems: Balancing Drug Loading and In Vivo Performance

    by Hayley B. Schultz, Miia Kovalainen, Karl F. Peressin, Nicky Thomas, Clive A. Prestidge

    Supersaturated silica-lipid hybrid (super-SLH) drug carriers are a recent strategy to improve the drug loading of oral solid lipid based formulations, however they are yet to be studied in vivo. This study investigates the in vivo pharmacokinetics (PK) of super-SLH containing ibuprofen (IBU) as a model drug, analysing the influence of supersaturated drug loading on oral bioavailability and assessing in vitro -- in vivo correlation (IVIVC). In addition, super-SLH was directly compared to spray dried SLH and Nurofen, to explore its potential advantages over the well-established and commercial formulations. Fasted male Sprague-Dawley rats were administered formulation suspensions (10 mg/kg IBU) via oral gavage and blood samples were acquired and analysed for drug content over 24 hours. In vivo, super-SLH with drug loads of 9.5 (99.5% saturated) and 19.3% w/w (227% saturated) achieved bioavailabilities equal to spray dried SLH and 2.2-fold greater than Nurofen. This effect diminished for super-SLH with a drug load of 29.1% w/w (389% saturated), which exhibited a bioavailability of less than Nurofen due to its greater extent of supersaturation and larger content of crystalline IBU. The super-SLH containing 19.3% w/w IBU provided an optimal PK performance, achieving the same degree of bioavailability enhancement as spray-dried SLH and requiring 63% less formulation. IVIVC was not observed due to the large improvement in performance by super-SLH in vivo compared to in vitro. These findings indicate the potential of super-SLH as an improved oral solid lipid based formulation strategy for enhancing oral bioavailability of poorly water-soluble drugs.


  • Open Access

    Biodegradation of inorganic drug delivery systems in subcutaneous conditions

    by M. Kovalainen, R. Kamakura, J. Riikonen, M. Finnilä, T. Nissinen, J. Rantanen, M. Niemelä, P. Perämäki, M. Mäkinen, K.H. Herzig, et al.


  • Open Access

    The effects of group and single housing and automated animal monitoring on urinary corticosterone levels in male C57BL/6 mice

    by Remi Kamakura, Miia Kovalainen, Juhani Leppäluoto, Karl-Heinz Herzig, Kari A. Mäkelä

    Mice are used extensively in physiological research. Automated home‐cage systems have been developed to study single‐housed animals. Increased stress by different housing conditions might affect greatly the results when investigating metabolic responses. Urinary corticosteroid concentration is considered as a stress marker. The aim of the study was to compare the effects of different housing conditions and an automated home‐cage system with indirect calorimetry located in an environmental chamber on corticosterone levels in mice. Male mice were housed in different conditions and in automated home‐cage system to evaluate the effects of housing and measuring conditions on urine corticosterone levels. Corticosterone levels in single‐housed mice in the laboratory animal center were consistently lower compared with the group‐housed mice. Single‐housed mice in a separate, small animal unit showed a rise in their corticosterone levels a day after they were separated to their individual cages, which decreased during the following 2 days. The corticosterone levels of group‐housed mice in the same unit were increased during the first 7 days and then decreased. On day 7, the corticosterone concentrations of group‐housed mice were significantly higher compared with that of single‐housed mice, including the metabolic measurement protocol. In conclusion, single housing caused less stress when compared with group‐housed mice. In addition, the urine corticosterone levels were decreased in single‐housed mice before the metabolic measurement started. Thus, stress does not affect the results when utilizing the automated system for measuring metabolic parameters like food and water intake and calorimetry.


  • Novel Delivery Systems for Improving the Clinical Use of Peptides

    by Miia Kovalainen, Juha Mönkäre, Joakim Riikonen, Ullamari Pesonen, Maria Vlasova, Jarno Salonen, Vesa-Pekka Lehto, Kristiina Järvinen, Karl-Heinz Herzig

    Peptides have long been recognized as a promising group of therapeutic substances to treat various diseases. Delivery systems for peptides have been under development since the discovery of insulin for the treatment of diabetes. The challenge of using peptides as drugs arises from their poor bioavailability resulting from the low permeability of biological membranes and their instability. Currently, subcutaneous injection is clinically the most common administration route for peptides. This route is cost-effective and suitable for self-administration, and the development of appropriate dosing equipment has made performing the repeated injections relatively easy; however, only few clinical subcutaneous peptide delivery systems provide sustained peptide release. As a result, frequent injections are needed, which may cause discomfort and additional risks resulting from a poor administration technique. Controlled peptide delivery systems, able to provide required therapeutic plasma concentrations over an extended period, are needed to increase peptide safety and patient compliancy. In this review, we summarize the current peptidergic drugs, future developments, and parenteral peptide delivery systems. Special emphasis is given to porous silicon, a novel material in peptide delivery. Biodegradable and biocompatible porous silicon possesses some unique properties, such as the ability to carry exceptional high peptide payloads and to modify peptide release extensively. We have successfully developed porous silicon as a carrier material for improved parenteral peptide delivery. Nanotechnology, with its different delivery systems, will enable better use of peptides in several therapeutic applications in the near future.


  • Systematic in vitro and in vivo study on porous silicon to improve the oral bioavailability of celecoxib

    by Joakim Riikonen, Alexandra Correia, Miia Kovalainen, Simo Näkki, Marko Lehtonen, Jukka Leppänen, Jimi Rantanen, Wujun Xu, Francisca Araújo, Jouni Hirvonen, et al.


  • Open Access

    Fat mass- and obesity-associated gene Fto affects the dietary response in mouse white adipose tissue

    by Justiina Ronkainen, Tuija J. Huusko, Raija Soininen, Eleonora Mondini, Francesca Cinti, Kari A. Mäkelä, Miia Kovalainen, Karl-Heinz Herzig, Marjo-Riitta Järvelin, Sylvain Sebert, et al.

    Common variants of human fat mass- and obesity-associated gene Fto have been linked with higher body mass index, but the biological explanation for the link has remained obscure. Recent findings suggest that these variants affect the homeobox protein IRX3. Here we report that FTO has a role in white adipose tissue which modifies its response to high-fat feeding. Wild type and Fto-deficient mice were exposed to standard or high-fat diet for 16 weeks after which metabolism, behavior and white adipose tissue morphology were analyzed together with adipokine levels and relative expression of genes regulating white adipose tissue adipogenesis and Irx3. Our results indicate that Fto deficiency increases the expression of genes related to adipogenesis preventing adipocytes from becoming hypertrophic after high-fat diet. In addition, we report a novel finding of increased Irx3 expression in Fto-deficient mice after high-fat feeding indicating a complex link between FTO, IRX3 and fat metabolism.


  • Neuropeptide Y in the noradrenergic neurones induces obesity and inhibits sympathetic tone in mice

    by L. H. Vähätalo, S. T. Ruohonen, Satu Mäkelä, Miia Kovalainen, Anne Huotari, K. A. Mäkelä, J. A. Määttä, Ilkka Miinalainen, Ralf Gilsbach, Lutz Hein, et al.

    Aim: Neuropeptide Y (NPY) co‐localized with noradrenaline in central and sympathetic nervous systems seems to play a role in the control of energy metabolism. In this study, the aim was to elucidate the effects and pathophysiological mechanisms of increased NPY in catecholaminergic neurones on accumulation of body adiposity.Methods: Transgenic mice overexpressing NPY under the dopamine‐beta‐hydroxylase promoter (OE‐NPYDβH) and wild‐type control mice were followed for body weight gain and body fat content. Food intake, energy expenditure, physical activity, body temperature, serum lipid content and markers of glucose homoeostasis were monitored. Thermogenic and lipolytic responses in adipose tissues, and urine catecholamine and tissue catecholamine synthesizing enzyme levels were analysed as indices of sympathetic tone.Results: Homozygous OE‐NPYDβH mice showed significant obesity accompanied with impaired glucose tolerance and insulin resistance. Increased adiposity was explained by neither increased food intake or fat absorption nor by decreased total energy expenditure or physical activity. Adipocyte hypertrophy and decreased circulating lipid levels suggested decreased lipolysis and increased lipid uptake. Brown adipose tissue thermogenic capacity was decreased and brown adipocytes filled with lipids. Enhanced response to adrenergic stimuli, downregulation of catecholamine synthesizing enzyme expressions in the brainstem and lower adrenaline excretion supported the notion of low basal catecholaminergic activity.Conclusion: Increased NPY in catecholaminergic neurones induces obesity that seems to be a result of preferential fat storage. These results support the role of NPY as a direct effector in peripheral tissues and an inhibitor of sympathetic activity in the pathogenesis of obesity.


  • Nanocarriers and the delivered drug: Effect interference due to intravenous administration

    by Maria A. Vlasova, Jussi Rytkönen, Joakim Riikonen, Olga S. Tarasova, Juha Mönkäre, Miia Kovalainen, Ale Närvänen, Jarno Salonen, Karl-Heinz Herzig, Vesa-Pekka Lehto, et al.


  • Nanocrystal-based per-oral itraconazole delivery: Superior in vitro dissolution enhancement versus Sporanox® is not realized in in vivo drug absorption

    by Annika Sarnes, Miia Kovalainen, Merja R. Häkkinen, Timo Laaksonen, Johanna Laru, Juha Kiesvaara, Jukka Ilkka, Olli Oksala, Seppo Rönkkö, Kristiina Järvinen, et al.


  • Effect of surface chemistry of porous silicon microparticles on glucagon-like peptide-1 (GLP-1) loading, release and biological activity

    by Anne Huotari, Wujun Xu, Juha Mönkäre, Miia Kovalainen, Karl-Heinz Herzig, Vesa-Pekka Lehto, Kristiina Järvinen